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effects may limit bone loss, but also reduce mortality in patients with kidney disease, and possibly attenuate the rate of progression of renal disease. The explanation for these benefi ts is elusive but may involve not only diminished levels of parathyroid hormone but perhaps attenuation of hormonal and proinfl ammatory systems that may promote scarring and fi brosis ( Figure 1 ). Despite the observed benefi ts with regard to mortality in patients with kidney disease, 2 and the reduction of albuminuria, 3 which is a perceived surrogate of renal protection, a lingering concern is the evidence in a number of patients of a decline in estimated glomerular fi ltration rate. Might the pleiotropic effects of vitamin D receptor activation possess both beneficial and detrimental eff ects on kidney function? Experimental studies have demonstrated that inadequate vitamin D receptor activation worsens diabetic nephropathy through increased fi bronectin production and decreased nephrin expression. 4 Moreover, vitamin D receptor activation suppresses high-glucoseinduced activation of the renin -angiotensin system and transforming growth factor-. 5 In other experimental models of nephropathy, vitamin D receptor activation attenuates renal interstitial fi brosis and limits epithelial-to-mesenchymal transition. 6 In clinical studies, vitamin D receptor activation facilitates an antiproteinuric response that is incremental to blood pressure reduction and renin -angiotensin system blockade. 3 Yet the increase in serum creatinine observed during these studies raises important questions about the overall long-term benefi t of vitamin D receptor activation for kidney function.
A number of important clues in the clinical literature provide perspective. First, the eff ect of vitamin D on serum creatinine was reversible aft er the cessation of therapy. 7 Second, in small studies, the reduction in creatinine clearance associated with vitamin D therapy was not seen in patients who had simultaneous measurement of glomerular fi ltration rate. 7 Th ird, other older studies, albeit small, have suggested that vitamin D receptor activation may alter creatinine metabolism and / or its handling by the kidney. 8 Consequently, the small but well-done study by Agarwal et al. 9 (this issue), in which they examined the eff ect of vitamin D receptor activation on creatinine metabolism and measured glomerular fi ltration rate, and its reversibility, is quite important. Although only 16 patients with chronic kidney disease were studied, Agarwal and colleagues 9 were able to demonstrate that a 7-day course of paricalcitol (2 g daily) resulted in an increase in serum creatinine and urine creatinine, while creatinine clearance did not change. Simultaneous measurement of glomerular filtration rate with iothalamate was not altered by paricalcitol therapy. Moreover, within 4 days of cessation of vitamin D therapy, the observed changes in creatinine generation and serum creatinine reversed back to near the baseline. In parallel with these changes were effects on both urea nitrogen excretion rate and serum urea nitrogen, indicating an early anabolic response to vitamin D receptor activation. Thus, there may be parallel effects of vitamin D receptor activation on protein and creatinine metabolism. These observations are not entirely surprising given older reports indicating that muscle tissue is a target of vitamin D receptor stimulation. 10 Small clinical studies have demonstrated that vitamin D treatment improves myopathy in patients with bone loss and results in increased muscle strength and gait and reduces falls. 11 It is conceivable that some of the beneficial impact of vitamin D receptor activation on survival in patients with chronic kidney disease could be related to its anabolic effects to improve skeletal and myocardial muscle function. This may be particularly important in patients with early evidence of either skeletal or myocardial muscle dysfunction. One has to wonder whether vitamin D receptor stimulation could even prevent muscle atrophy in patients with chronic kidney disease.
The importance of this small and straightforward study by Agarwal et al. 9 is that vitamin D receptor activation must be considered, at least in the short term, as a factor that can infl uence creatinine meta bolism. Th us, changes of serum creatinine, or a serum creatinine-based estimation of glomerular filtration rate, needs to be cautiously considered in patients receiving activated vitamin D. As we have learned with renin -angiotensin system blockers, which can induce a functional change in glomerular fi ltration rate that can be misinterpreted as nephrotoxicity, so can vitamin D receptor activation alter creatinine metabolism in a manner that could be misperceived as potential nephrotoxicity. However, as the authors appropriately point out, one should interpret these observations with care given that this is a small, short-term study. Th e observations that they provide in this important paper should prompt planning for longer-term trials of the overall infl uence of vitamin D receptor activation on protein and creatinine meta b olism in patients with chronic kidney disease. Th ese anabolic eff ects may help explain why vitamin D receptor activation may have beneficial effects on mortality in patients with chronic kidney disease.
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